Myofibroblast Ccn3 is regulated by Yap and Wwtr1 and contributes to adverse cardiac outcomes

Michael A Flinn1,2, Santiago Alvarez-Argote1,2, Makenna C Knas1,2

  • 1Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, United States.

Abstract

Insights

Targeting Yap and Wwtr1 in cardiac myofibroblasts improves heart function after myocardial infarction by reducing fibrosis. This study identifies Ccn3 as a key mediator of pathological remodeling, suggesting new therapeutic avenues.

Area of Science:

  • Cardiovascular Biology
  • Fibrosis Research
  • Molecular Mechanisms of Cardiac Remodeling

Background:

  • Yap and Wwtr1 regulate cardiac fibroblast differentiation post-injury.
  • Their specific role in activated myofibroblasts is not well understood.

Purpose of the Study:

  • To investigate the role of Yap and Wwtr1 in activated cardiac myofibroblasts following myocardial infarction.
  • To identify downstream factors mediating pathological cardiac remodeling.

Main Methods:

  • Genetic depletion of Yap and/or Wwtr1 in adult mouse myofibroblasts post-myocardial infarction.
  • Assessment of cardiac function, scar size, and fibrosis.
  • Single-cell RNA sequencing and in vitro knockdown studies.
  • Administration of recombinant CCN3 to mice post-myocardial infarction.

Main Results:

  • Depletion of Yap/Wwtr1 in myofibroblasts reduced scar size, interstitial fibrosis, and improved cardiac function.
  • Single-cell RNA sequencing revealed suppressed pro-fibrotic gene expression.
  • Yap/Wwtr1 depletion decreased CCN3 expression; CCN3 administration aggravated cardiac fibrosis and dysfunction.

Conclusions:

  • Yap/Wwtr1 depletion in myofibroblasts attenuates cardiac fibrosis and improves outcomes post-myocardial infarction.
  • CCN3 is identified as a downstream mediator of Yap/Wwtr1 in adverse cardiac remodeling.
  • Yap, Wwtr1, and CCN3 represent potential therapeutic targets for cardiac remodeling post-injury.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
18
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
14
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
13